Hands hold a light blue, pen-like medical auto-injector device.

Wegovy®

Semaglutide

Nicolette Lammers
none provided
The information on this page has been medically reviewed by
Make an appointment

What is Wegovy

Wegovy is a medicine with the active ingredient semaglutide. It is used as an aid in losing weight and maintaining weight in adults with obesity (BMI ≥ 30) or overweight (BMI 27–30) with weight-related health problems, such as high blood pressure, sleep apnea, or high cholesterol.

Within The Body Clinic, a doctor assesses during the consultation whether treatment with medication is suitable within a medical trajectory for weight management. More information about our medical approach can be found in our treatment program.

Wegovy is also available as a tablet that you take once a day. The Wegovy pill was approved in the European Union in July 2026. It is expected to become available in the Netherlands in November 2026, but this date has not yet been confirmed. Read everything about the Wegovy pill.

Dose escalation

Treatment with Wegovy starts with a low dose of 0.25 mg per week. The dose can then be increased step by step, depending on the effect and how well you tolerate the medication. There are at least four weeks between two dose increases. If the dose is increased every four weeks, the schedule looks like this:

MonthDose once a week
Month 10.25 mg
Month 20.5 mg
Month 31.0 mg
Month 41.7 mg
Month 52.4 mg
Month 67.2 mg

The 7.2 mg dose is only intended for people who need additional weight loss after at least four weeks on 2.4 mg. Your doctor will assess whether this makes sense for you.

How does Wegovy work?

Wegovy mimics the body's own hormone GLP-1. Your gut naturally produces this hormone after eating. It signals to your brain that you have eaten enough. Semaglutide works much longer than the natural hormone, so one injection per week is enough.

What it does in your body

  • Less hunger and feeling full sooner. GLP-1 sends a satiety signal to the brain. Many people also notice less 'food noise', the constant thinking about food.
  • Slower gastric emptying. Food stays in your stomach longer, so you feel full for longer.
  • Better blood sugar control. The pancreas releases more insulin when your blood sugar rises, and the release of glucagon decreases.

Wegovy is not a miracle cure. It works best combined with changes in diet and exercise, under the supervision of a doctor.

Instructions for using Wegovy

Wegovy comes as a single-use pre-filled injection pen. Always read the package leaflet or ask your doctor or pharmacist for an explanation.

Important:

  • One injection per week, on a fixed day.
  • The dose is increased gradually, starting with 0.25 mg per week.
  • Each pen contains one fixed dose and is discarded after use.

Injection site

  • Under the skin of the abdomen, thigh or upper arm.
  • Do not inject into a vein or muscle.
  • Always have a doctor or nurse demonstrate the first use.

Storage

  • In the refrigerator (2–8 °C), do not freeze, protect from light.
  • Outside the refrigerator: up to 28 days below 30 °C.

Read step by step how to inject Wegovy.

Semaglutide

Semaglutide is the active ingredient in Wegovy and is produced by Novo Nordisk. It belongs to the class of incretin mimetics and mimics the action of the natural gut hormone GLP-1 (glucagon-like peptide-1). After a meal, this hormone is normally released into the intestine. It stimulates the pancreas to release more insulin when blood sugar rises, reduces glucagon secretion from the liver, slows gastric emptying, and provides a stronger feeling of satiety in the brain. Through this combined action, semaglutide helps the body regulate blood sugar levels and, with a medical indication, supports weight loss and weight maintenance when used in combination with a healthy lifestyle and guidance from a doctor.

Wegovy and Weight Loss

Wegovy has been studied in randomized clinical trials regarding its effect on body weight in adults with obesity or overweight in combination with lifestyle advice (diet and exercise). These studies showed that semaglutide, combined with guidance and lifestyle adjustments, led to a substantial and clinically relevant weight loss in many participants compared to placebo.

Briefly explained: participants followed dietary and exercise advice and received a weekly injection of semaglutide or placebo. On average, body weight decreased more significantly in the semaglutide group. In the STEP 1 study, the following results were found after 68 weeks of treatment:

Results after 68 weeks (STEP 1 study)

Treatment groupAverage weight loss≥ 5%≥ 10%≥ 15%
Semaglutide 7.2 mg once a week−21%86%69%50%
Placebo + lifestyle guidance−2.4%31%12%5%

The effect gradually builds up during treatment. Results may vary per person; medication does not work for everyone and can cause side effects. Always read the package leaflet or SmPC and discuss expectations and risks with your treating physician.

Client wordt gewogen tijdens medisch afvallen traject bij The Body Clinic

Buy Wegovy? Only available by prescription via pharmacy

Wegovy is a prescription-only medicine. It is not freely available and can only be supplied with a prescription from a doctor. Dispensing takes place via the pharmacy. Online purchase without a prescription or outside a pharmacy is not permitted. Within The Body Clinic, a doctor assesses during the consultation whether treatment with medication is suitable within a medical weight management program. More information about our medical approach can be found in our treatment program.

View treatment

Wegovy price

The price of Wegovy is determined by the pharmacy and may vary per strength and dosage. Within The Body Clinic, a doctor assesses during the consultation whether treatment with medication is suitable within a medical weight management program. More information about our medical approach can be found in our treatment program.

Who is Wegovy suitable for

Wegovy can be prescribed to adults with:

  • BMI ≥ 30 (obesity), or
  • BMI 27–30 (overweight) with at least one weight-related condition, such as high blood pressure, high cholesterol, or sleep apnea. Use is always assessed individually by a doctor.

Wegovy prescription

Wegovy is available by prescription only. A BIG-registered doctor assesses whether you meet the medical criteria and can then write a prescription. Within The Body Clinic, a doctor assesses during the consultation whether treatment with medication is suitable within a medical weight management program. More information about our medical approach can be found in our treatment program.

Wegovy reimbursement by health insurance

Wegovy may be reimbursed in some cases for the treatment of type 2 diabetes, when other agents are insufficiently effective. For weight loss application, Wegovy usually falls outside the basic health insurance package. Inquire with your health insurer or pharmacy.

The substances in Wegovy

Wegovy is a pre-filled pen with a fixed strength per pen. Composition according to official product information:

  • Active ingredient: semaglutide.
  • Other excipients: disodium phosphate dihydrate, sodium chloride, water for injection.

Where do you inject Wegovy?

You inject Wegovy under the skin of your abdomen, thigh or the front of your upper arm, not into a vein or muscle. Read where and when to inject Wegovy.

Products:Wegovy®Ozempic®Mounjaro®Saxenda®
Pharmacist:Novo NordiskNovo NordiskEli LillyNovo Nordisk
Active ingredient:SemaglutideSemaglutideTirzepatideLiraglutide
Treatment type:ObesityType 2 DiabetesObesity and Type 2 DiabetesObesity
Dosage:0.25 - 2.4mg0.25 - 2.4mg2.5 - 15mg0,6 - 3,0mg
Administration:Injection, 1x per weekInjection, 1x per weekInjection, once a weekInjection, 1x per day
Approval phase:ApprovedApprovedApprovedApproved
Side effects:Common side effects include: nausea, diarrhea, vomiting, constipation, abdominal painCommon side effects include: nausea, diarrhea, vomiting, constipation, abdominal painCommon side effects include: nausea, diarrhea, decreased appetite, abdominal pain, reflux.Common side effects include: nausea, diarrhea, decreased appetite, headache, constipation

The difference between Mounjaro and Wegovy

  • Mounjaro application: weight loss/weight maintenance and type 2 diabetes. Wegovy: weight loss/weight maintenance.
  • Active ingredient and class Mounjaro: tirzepatide (GIP + GLP-1). Wegovy: semaglutide (GLP-1).
  • Dosage/frequency of use Both: once a week (dose escalation according to SmPC).
Leaflet & contraindications

Download the leaflet below and view the most common side effects of Wegovy.

Download leaflet
Do not use if hypersensitive (allergic) to semaglutide or any of the excipients
Do not use if there is a personal history of medullary thyroid carcinoma (MTC)
Do not use if Multiple Endocrine Neoplasia type 2 (MEN2) is present
Do not use during pregnancy, breastfeeding, or if planning to conceive

Side effects of Wegovy

Always read the package leaflet or SmPC for the complete and up-to-date list.

Commonly reported side effects of Wegovy (usually mild to moderate, especially during the dose escalation phase)

  • Nausea
  • Diarrhea
  • Decreased appetite
  • Vomiting
  • Constipation
  • Abdominal pain
  • Indigestion (heartburn)
  • Flatulence or reflux
  • Fatigue
  • Injection site reaction (itching, redness, or pain)

Less commonly reported side effects of Wegovy

  • Dizziness
  • Worsening of reflux symptoms
  • Changes in bowel movement patterns

Serious side effects — contact a doctor immediately

  • Persistent severe abdominal pain with or without vomiting (possible pancreatitis)
  • Severe or prolonged nausea, vomiting, or diarrhea (risk of dehydration or kidney damage)
  • Pain in the upper right abdomen or jaundice (possible gallbladder or liver problem)
  • Sudden worsening of vision (possible diabetic retinopathy)
  • Swelling of the face, lips, tongue, or throat (allergic reaction)

Practical tips for gastrointestinal complaints from Wegovy

  • Dose according to the escalation schedule; do not increase too quickly.
  • Eat calmly and smaller portions.
  • Avoid fatty or spicy food in the first weeks.
  • Drink small sips of water regularly.

Contraindications for using Wegovy

Wegovy must not be used:

  • in case of hypersensitivity to semaglutide or any of the excipients;
  • in case of severe stomach or bowel problems (such as gastroparesis);
  • in children and adolescents under 18;
  • during pregnancy or breastfeeding.

Note: Using Wegovy together with other blood glucose-lowering medicines may increase the risk of hypoglycaemia. Always discuss your full medication and medical history with the doctor during the consultation.

Pregnancy and breastfeeding

Do not use Wegovy during pregnancy or while breastfeeding. If you are planning a pregnancy, stop at least two months beforehand, in consultation with your doctor. Read more about pregnancy, contraception and surgery with Wegovy.

Sources

  • European Medicines Agency (EMA). Wegovy: EPAR, product information. ema.europa.eu. Version 30 March 2026, accessed 3 November 2026.
  • Wilding J.P.H. et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
Frequently Asked questions 

Is your question not listed? Then take a look at the frequently asked questions.

  • Wegovy (semaglutide) is used for weight loss and weight maintenance in people with obesity or overweight with weight-related conditions.

  • Semaglutide affects hunger and satiety, causing you to eat less and gradually lose weight.

  • In studies, participants lost an average of 14–15 kg after 68 weeks, depending on the dosage and lifestyle.

  • Most users notice a change in appetite within a few weeks.

  • No. Only with a prescription from a BIG-registered doctor and through a pharmacy.

  • Administer within 5 days; after that, skip it and continue according to the schedule. Do not take a double dose.

  • Your doctor will assess that based on your BMI, health, and medical history.

  • Wegovy and Ozempic contain the same active ingredient: semaglutide. The difference lies in what they are registered for. Ozempic is intended for type 2 diabetes, Wegovy for weight management in obesity or overweight. That is also why Wegovy goes up to a higher dose (2.4 mg or 7.2 mg). For weight loss, Wegovy is the medication that has been approved for this purpose.

  • In the STEP-1 study, participants on 2.4 mg lost an average of 14.9% of their body weight after 68 weeks. With a starting weight of 100 kilos, that is about 15 kilos. With the higher dose of 7.2 mg, the STEP UP study showed an average of about 21% after 72 weeks. These are averages from research. How much weight you lose depends on your starting weight, lifestyle and how your body responds to the medication.

  • Mainly gastrointestinal complaints such as nausea during the build-up phase. Read more about the side effects of Wegovy. In addition, it is not reimbursed and weight often returns after stopping.

  • Adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. A doctor assesses suitability during the intake.

  • No. Wegovy is not reimbursed in 2026, not even for type 2 diabetes. The Dutch Healthcare Institute advised against reimbursement in 2024 and the minister adopted that advice. If you have type 2 diabetes, your doctor can prescribe other medicines that are reimbursed under certain conditions.

  • That is not yet known. The Dutch Healthcare Institute is reassessing Wegovy, in the same process and with the same timetable as Mounjaro. The Scientific Advisory Council discussed Wegovy on 5 October 2026. The technical consultation is expected to start in early November 2026 (originally scheduled for 12–18 October). No dates have yet been set for the next steps or the advice.

    The Dutch Healthcare Institute is first assessing people with a BMI of 35 or higher, and people with a BMI of 30 or higher with a weight-related condition. This means that reimbursement for overweight (BMI 27 to 30) is not being assessed in this first step.

    Source: Dutch Healthcare Institute. Read more in our blog Will Mounjaro or Wegovy be reimbursed soon?

Book your treatment now or a free consultation

For a treatment or a non-binding consultation, you can call the central number directly or fill in the contact form on the contact page.